603207 Stock Overview
Shanghai Xiao Fang Pharmaceutical Co., Ltd produces and sells medicines in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shanghai Xiao Fang Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥26.31 |
| 52 Week High | CN¥39.50 |
| 52 Week Low | CN¥20.50 |
| Beta | 0 |
| 11 Month Change | 10.31% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603207 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 10.0% | 15.7% | 15.5% |
| 1Y | n/a | -1.6% | 1.2% |
Return vs Industry: Insufficient data to determine how 603207 performed against the CN Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 603207 performed against the CN Market.
Price Volatility
| 603207 volatility | |
|---|---|
| 603207 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 4.5% |
Stable Share Price: 603207's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: Insufficient data to determine 603207's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 548 | n/a | www.xf-pharma.com |
Shanghai Xiao Fang Pharmaceutical Co., Ltd produces and sells medicines in China. It offers medicines in the areas of gastroenterology, dermatology, orthopedics, otorhinolaryngology, and disinfection. Shanghai Xiao Fang Pharmaceutical Co., Ltd was founded in 1993 and is based in Shanghai, China.
Shanghai Xiao Fang Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603207 fundamental statistics | |
|---|---|
| Market cap | CN¥4.21b |
| Earnings (TTM) | CN¥204.48m |
| Revenue (TTM) | CN¥473.68m |
20.6x
P/E Ratio8.9x
P/S RatioIs 603207 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603207 income statement (TTM) | |
|---|---|
| Revenue | CN¥473.68m |
| Cost of Revenue | CN¥160.05m |
| Gross Profit | CN¥313.62m |
| Other Expenses | CN¥109.15m |
| Earnings | CN¥204.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.28 |
| Gross Margin | 66.21% |
| Net Profit Margin | 43.17% |
| Debt/Equity Ratio | 0.09% |
How did 603207 perform over the long term?
See historical performance and comparison